3 completed, 1 terminated. 1 Not applicable, 1 Phase 2, 1 Phase 3, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 1 | Completed 1 |
| Phase 2 | 1 | Completed 1 |
| Phase 3 | 1 | Completed 1 |
| Phase 4 | 1 | Terminated 1 |
Follow Oxis: new trials by email Literature Review of Oxis trials Research Report on Oxis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| ANTES B+ Clinical Trial Trelegy Ellipta 100/62.5/25Mcg Inh 30D, Brimica, Duaklir - Chronic Obstructive Pulmonary Disease | Phase 4 | Terminated | Fundacio Privada Mon Clinic Barcelona | 48 | 2024-02-29 | 2025-08-14 |
| Single-dose Crossover Study to Investigate Pharmacodynamics of AZD3199 AZD3199, Formoterol, Placebo - Asthma, Airway Obstruction | Phase 2 | Completed | AstraZeneca | 37 | 2008-08-01 | 2014-05-19 |
| Evaluation of Efficacy and Safety of Formoterol in Patients With COPD Compared With Placebo in Patients in Japan, EU Formoterol Turbuhaler® 4.5mg, Formoterol Turbuhaler® 9 mg, Turbuhaler® placebo - Chronic Obstructive Pulmonary Disease | Phase 3 | Completed | AstraZeneca | 613 | 2007-12-01 | 2012-10-25 |
| Effect of Symbicort on GR Localisation in Asthma Placebos, Formoterol Inhalant Powder, Budesonide Powder - Asthma | Not applicable | Completed | Imperial College London | 10 | 2004-11-01 | 2019-09-27 |
Asthma (2) · Pulmonary Disease, Chronic Obstructive (2) · Airway Obstruction (1) · Respiratory Aspiration (1)
AstraZeneca (2) · Fundacio Privada Mon Clinic Barcelona (1) · Imperial College London (1)
Bulgaria (1) · Denmark (1) · Japan (1) · Romania (1) · Russia (1) · Spain (1) · Sweden (1) · Ukraine (1) · United Kingdom (1)
Lars-Goran Carlsson, MD (1) · Miron A Bogdan, MD (1) · Prof Leif Bjermer, MD, PhD (1) · Sergei A Kharitonov, MD PhD (1)
PMID 21903370, PMID 22085439, PMID 23907810
2023 (1)